U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H13N3O5
Molecular Weight 243.2166
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CYTARABINE

SMILES

NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O

InChI

InChIKey=UHDGCWIWMRVCDJ-CCXZUQQUSA-N
InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1

HIDE SMILES / InChI
Molecular Formula C9H13N3O5
Molecular Weight 243.2166
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Sources: www.accessdata.fda.gov/drugsatfda_docs/label/2011/021041s023lbl.pdf
Curator's Comment: Description was created using several sources including: http://www.ebi.ac.uk/chebi/searchId.do?chebiId=28680 http://www.tandfonline.com/doi/abs/10.1517/17425247.2010.527330

Cytarabine is a pyrimidine nucleoside analog. Cytarabine or cytosine arabinoside (Cytosar-U or Depocyt) is a chemotherapy agent used mainly in the treatment of cancers of white blood cells such as acute myeloid leukemia (AML) and non-Hodgkin lymphoma. It also has antiviral and immunosuppressant properties. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. It is a cell cycle phase-specific, affecting cells only during the S phase of cell division. Intracellularly, cytarabine is converted into cytarabine-5-triphosphate (ara-CTP), which is the active metabolite. The mechanism of action is not completely understood, but it appears that ara-CTP acts primarily through inhibition of DNA polymerase. Incorporation into DNA and RNA may also contribute to cytarabine cytotoxicity. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture.The drug has a short plasma half-life, low stability and limited bioavailability. Overdosing of patients with continuous infusions may lead to side effects. Thus, various prodrug strategies and delivery systems have been explored extensively to enhance the half-life, stability and delivery of cytarabine. Alternative, delivery systems of cytarabine have emerged for the treatment of different cancers. The liposomal-cytarabine formulation has been approved for the treatment of lymphomatous meningitis.

CNS Activity

CNS Active
3913

Originator

University of California-Berkeley
3
Curator's Comment: Cytarabine was first synthesized in 1959 by Richard Walwick, Walden Roberts, and Charles Dekker at the University of California, Berkeley. It was approved by the United States Food and Drug Administration in June 1969, and was initially marketed in the U.S. by Upjohn under the trade name Cytosar-U and is at present manufactured by Pfizer, Sicor Pharmaceuticals and Teva. CYTOSAR (cytarabine injection) was developed in September 1994 Dana-­Farber Cancer Institute and is manufactured by Pfizer and Perrigo. DEPOCYT - (cytarabine injection, lipid complex) manufactured by Manufactured by: Pacira Pharmaceuticals Inc., distributed by Sigma-Tau Pharmaceutical, Inc. is an intrathecal cancer chemotherapeutic agent approved by FDA is used for the treatment of lymphomatous meningitis.

Approval Year

1969
24
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase III
656
Unknown

Approved Use

Unknown
Lymphomatous meningitis
3
Sources: www.accessdata.fda.gov/drugsatfda_docs/label/2011/021041s023lbl.pdf
 Primary
Approved
8429
CYTARABINE

Approved Use

Cytarabine in combination with other approved anticancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and children. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of cytarabine injection (preservative-free only) is indicated for the prophylaxis and treatment of meningeal leukemia.

Launch Date

1969
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
62.2 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf
100 mg/m² 1 times / day multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: DAUNORUBICIN
DAUNORUBICIN
 CYTARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1900 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf
100 mg/m² 1 times / day multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: DAUNORUBICIN
DAUNORUBICIN
 CYTARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
40.4 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s000lbl.pdf
100 mg/m² 1 times / day multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: DAUNORUBICIN
DAUNORUBICIN
 CYTARABINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
80 h
REVIEW
https://www.ncbi.nlm.nih.gov/pubmed/12162758
50 mg single, intrathecal
dose: 50 mg
route of administration: Intrathecal
experiment type: SINGLE
co-administered:
CYTARABINE unknown
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6223674
Page: p.363, 366
unhealthy, 16-76
n = 6
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/6223674
Page: p.363, 366
Disc. AE: Cerebellar disorder NOS, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Cerebellar disorder NOS (grade 4, 66.7%)
Diarrhea (grade 3, 66.7%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/6223674
Page: p.363, 366
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7306918
Page: p.2578
unhealthy, 16-76
n = 6
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/7306918
Page: p.2578
Disc. AE: Cerebellar disorder NOS, Cerebellar disorder NOS...
AEs leading to
discontinuation/dose reduction:
Cerebellar disorder NOS (grade 4, 33.3%)
Cerebellar disorder NOS (grade 5, 16.7%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7306918
Page: p.2578
3 g/m2 2 times / day multiple, intravenous
MTD
Dose: 3 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 3 g/m2, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6223674
Page: p.366
unhealthy, 16-76
n = 27
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 27
Sources:
https://pubmed.ncbi.nlm.nih.gov/6223674
Page: p.366
Sources:
https://pubmed.ncbi.nlm.nih.gov/6223674
Page: p.366
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Page: p.1
Disc. AE: Bone marrow depression, Leukopenia...
AEs leading to
discontinuation/dose reduction:
Bone marrow depression
Leukopenia
Thrombocytopenia
Anemia
Nausea
Vomiting
Diarrhea
Abdominal pain
Oral ulceration
Hepatic dysfunction NOS
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Page: p.1
AEs

AEs

AESignificanceDosePopulation
Diarrhea grade 3, 66.7%
Disc. AE
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6223674
Page: p.363, 366
unhealthy, 16-76
n = 6
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/6223674
Page: p.363, 366
Cerebellar disorder NOS grade 4, 66.7%
Disc. AE
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/6223674
Page: p.363, 366
unhealthy, 16-76
n = 6
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/6223674
Page: p.363, 366
Cerebellar disorder NOS grade 4, 33.3%
Disc. AE
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7306918
Page: p.2578
unhealthy, 16-76
n = 6
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/7306918
Page: p.2578
Cerebellar disorder NOS grade 5, 16.7%
Disc. AE
4.5 g/m2 2 times / day multiple, intravenous
Highest studied dose
Dose: 4.5 g/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 4.5 g/m2, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7306918
Page: p.2578
unhealthy, 16-76
n = 6
Health Status: unhealthy
Condition: Acute leukemia
Age Group: 16-76
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/7306918
Page: p.2578
Abdominal pain Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Page: p.1
Anemia Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Page: p.1
Bone marrow depression Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Page: p.1
Diarrhea Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Page: p.1
Hepatic dysfunction NOS Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Page: p.1
Leukopenia Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Page: p.1
Nausea Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Page: p.1
Oral ulceration Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Page: p.1
Thrombocytopenia Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Page: p.1
Vomiting Disc. AE
100 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 100 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Acute non-lymphocytic leukemia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf
Page: p.1
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1737

inhibitor
1587

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1925
 yes [IC50 6.6 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1737
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:28680
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28680
MolPort
MolPort-001-792-509
https://www.molport.com/shop/molecule-link/MolPort-001-792-509
Selleck Chemicals
Cytarabine(Cytosar-U)
http://www.selleckchem.com/products/Cytarabine(Cytosar-U).html
ZINC
ZINC000003795098
http://zinc15.docking.org/substances/ZINC000003795098
eMolecules
1012736
https://www.emolecules.com/cgi-bin/more?vid=1012736
PubMed

PubMed

TitleDatePubMed
Ocular toxicology.
1994 Dec
Differential p53 phosphorylation and activation of apoptosis-promoting genes Bax and Fas/APO-1 by irradiation and ara-C treatment.
1998 Jul
[Topotecan: a new field of use].
1999 Nov-Dec
Differential transport of cytosine-containing nucleosides by recombinant human concentrative nucleoside transporter protein hCNT1.
2000 Jan-Feb
Oxidative stress interferes with cancer chemotherapy: inhibition of lymphoma cell apoptosis and phagocytosis.
2000 Jul 1
Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.
2000 May 1
Acute neurotoxicity in children with B-lineage acute lymphoblastic leukemia (B-ALL) treated with intermediate risk protocols.
2000 Nov
Misdiagnosis of broad-complex tachycardia.
2000 Nov-Dec
Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity.
2000 Sep
Treatment for primary CNS lymphoma: the next step.
2000 Sep
Lenograstim and filgrastim effects on neutrophil motility in patients undergoing chemotherapy: evaluation by computer-assisted image analysis.
2001 Apr
Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation.
2001 Apr
Parotid mucoepidermoid carcinoma following chemotherapy for childhood acute lymphoblastic leukemia.
2001 Apr-May
Prognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia.
2001 Apr-May
[Philadelphia chromosome-positive acute lymphoblastic leukemia with monosomy 7 successfully treated with intermediate- and high-dose ara-C].
2001 Feb
Primary central nervous system lymphoma in childhood presenting as progressive panhypopituitarism.
2001 Feb
Characterization of DNA fragmentation events caused by genotoxic and non-genotoxic agents.
2001 Feb 20
[Palpable mantel cell lymphoma in the breast].
2001 Feb 3
Allogeneic bone marrow transplantation in children failing prior autologous bone marrow transplantation.
2001 Jan
Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance.
2001 Jan
A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation.
2001 Jan
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients.
2001 Jan
De novo acute myeloid leukemia in the elderly; a consistent fraction of long-term survivors by standard-dose chemotherapy.
2001 Jan
Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis.
2001 Jan
Chemotherapy and marrow transplantation for congenital leukaemia.
2001 Jan
Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells.
2001 Jan 1
Bcl-X(L)-caspase-9 interactions in the developing nervous system: evidence for multiple death pathways.
2001 Jan 1
Porcine Choroid plexus epithelial cells in culture: regulation of barrier properties and transport processes.
2001 Jan 1
Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study.
2001 Jan 3
Upregulation of preprodynorphin and preproenkephalin mRNA expression by selective activation of group I metabotropic glutamate receptors in characterized primary cultures of rat striatal neurons.
2001 Jan 31
Evidence against apoptosis as a major mechanism for reproductive cell death following treatment of cell lines with anti-cancer drugs.
2001 Jan 5
Toxic epidermal necrolysis after the use of high-dose cytosine arabinoside.
2001 Jan-Feb
Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols.
2001 Mar
Combination chemotherapy utilizing continuous infusion of intermediate-dose cytarabine for refractory or recurrent acute myeloid leukemia.
2001 Mar
Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.
2001 Mar 15
Circumvention of ara-C resistance by aphidicolin in blast cells from patients with AML.
2001 Mar 2
Patents

Patents

03950325
3
JP2000512843A
3
JP2004518776A
9
JP2006502184A
41
JP2006521885A
8
JP2006523256A
7
JP2007533670A
6
JP2008245583A
3
JP2008510795A
76
JP2008533019A
34
JP2011500014A
3
JP2011528275A
455
JP2012500104A
107
JP4395065B2
11
JP4397691B2
21
JPH05186354A
4
JPH05310819A
3
JPS05537166A
3
JPS527975A
3
JPS5665829A
3

Sample Use Guides

In Vivo Use Guide
Induction therapy: DepoCyt (cytarabine liposome injection), 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 14 days for 2 doses (weeks 1 and 3). Consolidation therapy: DepoCyt, 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 14 days for 3 doses (weeks 5, 7 and 9) followed by 1 additional dose at week 13. Maintenance: DepoCyt, 50 mg, administered intrathecally (intraventricular or lumbar puncture) every 28 days for 4 doses (weeks 17, 21, 25 and 29).
Route of Administration: Intratracheal
In Vitro Use Guide
Curator's Comment: The effect of Ara-C (0.1 μM) treatment on HUVEC proliferation alone or in drug combinations compared to drug-free control cultures. Results are expressed as mean percentage ± SEM from three independent experiments (six replicates per condition) relative to corresponding untreated control cultures.
Human umbilical vein endothelial cells (HUVECs) and human osteosarcoma cell line (Cal72) were incubated with various concentrations of Cytarabine (Ara-C) (0.01–20 μM) for 3 days
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:40:24 GMT 2023
Edited
by admin
on Sat Dec 16 16:40:24 GMT 2023
Record UNII
04079A1RDZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CYTARABINE
EMA EPAR   EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
CYTARABINE [USP-RS]
Common Name English
CYTARABINE [HSDB]
Common Name English
CYTOSAR-U
Brand Name English
CYTARABINE [EP MONOGRAPH]
Common Name English
CYTARABINE [WHO-IP]
Common Name English
CYTARABINUM [WHO-IP LATIN]
Common Name English
DEPOCYT
Brand Name English
ARACYTIN
Common Name English
U-19,920
Code English
CYTARABINE [USAN]
Common Name English
CYTARABINE LIPOSOME
VANDF  
Common Name English
CYTARABINE [VANDF]
Common Name English
ARACYTIDINE
Common Name English
SPONGOCYTIDINE
Common Name English
CYTARABINE [MI]
Common Name English
ARABINOCYTOSINE
Common Name English
CYTARABINE [ORANGE BOOK]
Common Name English
ARA-C
Common Name English
CYTARABINE LIPOSOME [VANDF]
Common Name English
CYTARABINE [USP IMPURITY]
Common Name English
1-.BETA.-D-ARABINOFURANOSYLCYTOSINE
Common Name English
Cytarabine [WHO-DD]
Common Name English
VYXEOS COMPONENT CYTARABINE
Brand Name English
NSC-287459
Code English
U 19920A
Common Name English
CYTARABINE [MART.]
Common Name English
CYTARABINOSIDE
Common Name English
CYTARABINE [JAN]
Common Name English
U-19920
Code English
ARACYTINE
Common Name English
cytarabine [INN]
Common Name English
CYTARABINE [EMA EPAR]
Common Name English
2(1H)-PYRIMIDINONE, 4-AMINO-1-.BETA.-D-ARABINOFURANOSYL-
Common Name English
CYTARABINE [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
WHO-ATC L01XY01
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
FDA ORPHAN DRUG 234806
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
NDF-RT N0000175595
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
NDF-RT N0000000233
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
EMA ASSESSMENT REPORTS DEPOCYT (AUTHORIZED: MENINGEAL NEOPLASMS)
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
FDA ORPHAN DRUG 265808
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
NCI_THESAURUS C1557
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
FDA ORPHAN DRUG 73393
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
LIVERTOX NBK548291
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
WHO-ATC L01BC01
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
EU-Orphan Drug EU/3/11/942
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
WHO-VATC QL01BC01
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
Code System Code Type Description
RXCUI
968804
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
ALTERNATIVE
ECHA (EC/EINECS)
205-705-9
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
PRIMARY
EPA CompTox
DTXSID3022877
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
PRIMARY
DRUG BANK
DB00987
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
PRIMARY
EVMPD
SUB06880MIG
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
PRIMARY
NCI_THESAURUS
C408
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
PRIMARY
RXCUI
3041
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
PRIMARY
DAILYMED
04079A1RDZ
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
PRIMARY
MERCK INDEX
m4051
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
PRIMARY Merck Index
PUBCHEM
6253
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
PRIMARY
WIKIPEDIA
CYTARABINE
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
PRIMARY
ChEMBL
CHEMBL803
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
PRIMARY
RS_ITEM_NUM
1162002
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
PRIMARY
FDA UNII
04079A1RDZ
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
PRIMARY
IUPHAR
4827
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
PRIMARY
DRUG CENTRAL
770
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
PRIMARY
CAS
147-94-4
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
PRIMARY
MESH
D003561
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
PRIMARY
CHEBI
28680
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
PRIMARY
SMS_ID
100000089874
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
PRIMARY
INN
1709
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
PRIMARY
HSDB
3049
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
PRIMARY
NSC
287459
Created by admin on Sat Dec 16 16:40:27 GMT 2023 , Edited by admin on Sat Dec 16 16:40:27 GMT 2023
PRIMARY
Related Record Type Details
DEOXYCYTIDINE KINASE
METABOLIC ENZYME -> SUBSTRATE
kcat
DEOXYCYTIDINE KINASE
METABOLIC ENZYME -> SUBSTRATE
Km
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of CYTARABINE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of ASPACYTARABINE
PRODRUG -> METABOLITE ACTIVE
Structure of URACIL ARABINOSIDE
METABOLITE INACTIVE -> PARENT
Produced via Cytidine deaminase exposure.
PLASMA
Structure of CYTIDINE TRIPHOSPHATE
METABOLITE ACTIVE -> PARENT
PLASMA
Structure of ELACYTARABINE
PRODRUG -> METABOLITE ACTIVE
Structure of CYTARABINE TRIPHOSPHATE
METABOLITE ACTIVE -> PARENT
Structure of URACIL ARABINOTIDE
METABOLITE ACTIVE -> PARENT
PLASMA
Structure of CYTARABINE 5'-PHOSPHATE
METABOLITE -> PARENT
Related Record Type Details
Structure of CYTIDINE
IMPURITY -> PARENT
Structure of CYTOSINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of URACIL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of URACIL ARABINOSIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of URACIL ARABINOSIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of URACIL
IMPURITY -> PARENT
Structure of 5-METHYLCYTIDINE
IMPURITY -> PARENT
Structure of ANCITABINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of URIDINE
IMPURITY -> PARENT
Structure of URACIL
IMPURITY -> PARENT
Related Record Type Details
Structure of CYTARABINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966